Review of the various drugs in current clinical use showed that over 50 of them may cause a purely sensory or mixed sensorimotor neuropathy. These include antimicrobials, such as isoniazid, ethambutol, ethionamide, nitrofurantoin, and metronidazole; antineoplastic agents, particularly vinca alkaloids; cardiovascular drugs, such as perhexiline and hydrallazine; hypnotics and psychotropics, notably methaqualone; antirheumatics, such as gold, indomethacin, and chloroquine; anticonvulsants, particularly phenytoin; and other drugs, including disulfiram, calcium carbimide, and dapsone.
Introduction
Various drugs may cause peripheral nerve damage when used therapeutically.1 2Some, such as thalidomide and clioquinol, have been withdrawn from clinical use, while others are still freely prescribed. In this review we deal only with the second group of drugs, particularly those that have recently been recognised or suspected to be neurotoxic. We consider only those forms of neuropathy resulting from the therapeutic use of such drugs, and do not discuss the complications of drug addiction. 3 Awareness of the possibility of drug-induced peripheral nerve damage is important because of the ever-increasing number of therapeutic agents being introduced into clinical practice, and prompt recognition of this complication is imperative if severe neurological deficits are to be avoided. The incidence of druginduced peripheral neuropathy is difficult to establish, since the association with drug treatment is not always recognised, mild forms are easily overlooked, and subclinical disorders are probably more frequent than is generally appreciated.4 5 
Pathogenesis
Experimental studies have clarified the pathogenesis of certain drug-induced neuropathies,7 but the basic mechanisms are generally still poorly understood. Because these disorders are potentially reversible the opportunities for histological and other studies of peripheral nerve in man are limited. Nevertheless, with some exceptions, such as perhexiline neuropathy, in which segmental demyelination is prominent,8 axonal degeneration is the major pathological process in most drug-induced neuropathies.
The mechanism of action of some drugs is relatively well understood. Vincristine A predominantly motor neuropathy may occasionally develop in patients treated with imipramine62 63 and amitriptyline,64 but such cases have not been studied fully. Reports of "neuritis" developing in patients receiving chlorprothixene and of acroparaesthesiae in those receiving phenelzine are difficult to evaluate.2 22 Sensory neuropathy has been described in patients addicted to glutethimide but is not a complication of conventional use of the drug.5 66 ANTIRHEUMATIC 
DRUGS
Peripheral neuropathy occurs in 0 5-1 ',, of patients with rheumatoid arthritis who have gold treatment.67"'i Motor disorders are prominent and sensory symptoms may be inconspicuous. An abrupt onset and rapid progression in some cases, and associated facial diplegia and raised protein concentration in cerebrospinal fluid may mimic acute postinfective polyneuropathy. Few cases have been studied electrophysiologically or pathologically but axonal degeneration appears to be the main process.'; Indomethacin has also been implicated in causing a neuropathy. A report on four patients with a sensorimotor neuropathy and two with sensory symptoms only suggested that the drug was responsible.-" Electromyographic studies showed considerable slowing of motor conduction velocities in one case. Further studies are needed to determine the incidence of this complication.
Chloroquine may cause a mild sensorimotor neuropathy as well as a severe vacuolar myopathy.71-7' Histological studies have shown both axonal degeneration and damage to Schwann cells. 74 Peripheral neuropathy has been reported in patients treated with penicillamine,75 but less often than the myasthenic syndrome that develops in some patients treated with the drug. The mechanism of the neuropathy may be related to that caused by isoniazid, since penicillamine has an antipyridoxine effect. Paraesthesiae and muscle weakness have been reported in some patients treated with phenylbutazone but are difficult to evaluate.7
ANTICONVULSANTS
Patients receiving long-term phenytoin treatment may develop a predominantly sensory polyneuropathy that is usually mild and rarely causes symptoms.78 79 The incidence of this complication is uncertain, but signs of peripheral nerve disorders, such as depression of tendon reflexes, are found increasingly often in patients receiving prolonged treatment. 80 Electrophysiological studies have shown that subclinical lesions are common and that the neuropathy is of the "dying-back" axonal degeneration type.80 The drug also has acute, reversible effects, particularly on slow-conducting motor nerve fibres. 8 
Conclusions
Drugs used in treating various conditions may cause peripheral nerve damage. This may be clinically manifest, but in many instances is asymptomatic. We suggest that a careful neurological examination and studies of motor and sensory nerve conduction should be performed in patients who complain of paraesthesiae, pain, muscle cramps, weakness, or other abnormal sensations during drug treatment. Investigation of such patients and of patients without symptoms who are being treated with drugs that are known or suspected to be neurotoxic will allow the incidence of drug-induced peripheral nerve damage to be determined more precisely. 
